Lv1
70 积分 2024-07-03 加入
230MO Pembrolizumab plus anlotinib as first-line treatment in patients of CPS≥1 with recurrent or metastatic head and neck squamous-cell carcinoma: A prospective phase II study
24天前
已完结
Ramucirumab in combination with pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma: a single-centre, phase 1/2 trial
24天前
已完结
Pembrolizumab with or Without Lenvatinib As First-line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC): Phase 3 LEAP-010 Study
27天前
已完结
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
1个月前
已完结
Nivolumab for recurrent squamous-cell carcinoma of the head and neck
2个月前
已完结
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
2个月前
已完结
Immune Checkpoint Inhibitors for Advanced Biliary Tract Cancer
2个月前
已完结
A phase II study of nivolumab in patients with advanced refractory biliary tract cancers (BTC)
3个月前
已关闭
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
3个月前
已完结
[Comprehensive treatment strategies for head neck tumors]
3个月前
已完结
皖公网安备34019202002308
